Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somavert in Acromegaly With Cardiac Impairment
NCT00552851Phase 4Unknown
- Start
- Jun 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegvisomant in acromegaly. Primary endpoint: Peak systolic strain rate at 1 year. Status: unknown.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT00552851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552851.